• Publications
  • Influence
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease. Expand
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
TLDR
Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. Expand
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
TLDR
B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response. Expand
Cognitive impairment associated with adjuvant therapy in breast cancer
TLDR
Adjuvant chemotherapy in women with breast cancer can be associated with deteriorations in memory and this may persist over time, and the addition of tamoxifen may lead to more widespread memory deficits. Expand
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
TLDR
VOD is a common complication of bone marrow transplantation and has a specific clinical presentation, which usually allows diagnosis without the need of liver biopsy, and is the third leading cause of death in allogeneic graft recipients, and the second leading cause in patients receiving autologous transplants. Expand
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human
TLDR
Administering trastuzumab with paclitaxel after AC increases incidence of congestive heart failure and lesser CD, and potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy. Expand
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
TLDR
Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer, and the quantitative analyses presented can assist health care providers and women in weighing the risks and benefits of tamoxIFen for reducing breast cancer risk. Expand
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
TLDR
Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity. Expand
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
TLDR
The Update Committee concluded that no revisions to the existing ASCO recommendations were warranted and recommended regular history, physical examination, and mammography for breast cancer follow-up. Expand
...
1
2
3
4
5
...